FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 742 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Breaking News: Supreme Court Upholds the Affordable Care Act June 17, 2021 Διαφημιστείτε January 18, 2019 FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... May 13, 2026 FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 Load more HOT NEWS For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... How our global activity is tackling cancer prevention in low- and... ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21...
